(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 January 2010 (07.01.2010)

PCT

(10) International Publication Number
WO 2010/003108 A3

(51) International Patent Classification:
C07K 14/715 (2006.01) *C12N 15/62* (2006.01)
C07K 16/24 (2006.01)

(21) International Application Number:
PCT/US2009/049603

(22) International Filing Date:
2 July 2009 (02.07.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/134,095	2 July 2008 (02.07.2008)	US
61/134,096	2 July 2008 (02.07.2008)	US
61/134,101	2 July 2008 (02.07.2008)	US
61/134,099	2 July 2008 (02.07.2008)	US
61/134,097	2 July 2008 (02.07.2008)	US
61/134,100	2 July 2008 (02.07.2008)	US
61/134,098	2 July 2008 (02.07.2008)	US
61/180,097	20 May 2009 (20.05.2009)	US

(71) Applicant *(for all designated States except US)*: **TRUBION PHARMACEUTICALS, INC.** [US/US]; 2401 Fourth Avenue, Suite 1050, Seattle, WA 98121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LOFQUIST, Alan, Keith** [US/US]; 9422 N.E. 130th Place, Kirkland, WA 98034 (US). **MOHLER, Kendall, Mark** [US/US]; 14200 Sandy Hook Road, Poulsbo, WA 98370 (US). **BAUM, Peter, Robert** [US/US]; 6027 - 34th Avenue N.E., Seattle, WA 98115 (US). **THOMPSON, Peter, Armstrong** [US/US]; 14075 N.E. 30th Place, Bellevue, WA 98007 (US). **MISHER, Lynda** [US/US]; 10614 - 10th Place N.E., Seattle, WA 98125 (US).

(74) Agents: **SLEATH, Janet** et al.; Speckman Law Group PLLC, 1201 Third Avenue, Suite 330, Seattle, WA 98101 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
25 February 2010

(54) Title: TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS

(57) Abstract: This disclosure provides a multi-target fusion protein composed of a TNF-α antagonist domain and another binding domain antagonistic for a heterologous target, such as IL6, RANKL, IL7, IL17A/F, TWEAK, CSF2, IGF1, IGF2 or BLyS/APRIL, or agonistic for a heterologous target, such as IL10. The multi-specific fusion protein may also include an intervening domain that separates the binding domains and allows for dimerization. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

WO 2010/003108 A3